Glow (Pen)

Description

GLOW research pen — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

This listing is GLOW in pen format (70mg fill) — the same research material as our GLOW vials, supplied in a pre-formatted research pen for laboratories that prefer logged, repeatable handling over loose vials. GLOW combines three synthetic peptides — the copper tripeptide GHK-Cu, the gastric pentadecapeptide BPC-157, and TB-500, which the vial batch report identified as full-length thymosin β4. Each has its own animal and cell-culture literature; the mixture has none. Laboratory research only; the pen is a handling format, not an instruction.

Full research overview, study table & references → GLOW in Canada: research guide (component guides: BPC-157 · TB-500 · GHK-Cu)

Identity at a glance

Batch documentation: a batch-specific COA for the GLOW pen has not been posted yet — see the COA library. Reports for the vial listings, where posted, are on those pages.

What researchers have looked at

• GHK-Cu, fibroblast culture (1988): collagen synthesis rose from about 10⁻¹² M and peaked at 10⁻⁹ M with no change in cell number^[1]. Rat wound chambers (1993): concentration-dependent increases in dry weight, DNA, collagen and glycosaminoglycans, with collagen I and III mRNA up and TGF-β mRNA unchanged^[2].
• GHK-Cu, rat ACL reconstruction (2015): less knee laxity and stiffer grafts at 6 weeks, but no difference from saline at 12 weeks once injections stopped^[3].
• BPC-157, rat Achilles (2003): higher failure load and better function after transection versus saline^[4]. Thymosin β4, rat wounds (1999): re-epithelialisation up 42% at day 4 and 61% at day 7^[5].
• Limits: the only combination study (BPC-157 + TB-500, 32 rats, 2026) found no added benefit over either peptide alone^[6]; a 2025 systematic review of BPC-157 found no clinical safety data^[7]; nothing tests the three-way blend, and no human study supports any use of GLOW.

Storage and handling

• Follow the label: keep the pen cool, dry and out of light, and do not subject it to repeated freeze–thaw.
• Log the batch number and dates of receipt and first use, as with any research material. No protocol or administration information is provided here.

Vial strength: GLOW 70MG. Other pens are on the peptide pens page; the whole range is on our buy peptides online in Canada page. Canada Post from inside Canada (shipping policy).

Frequently asked questions

What is the GLOW pen?

The same synthetic GLOW supplied in a pre-formatted research pen rather than a loose vial, for laboratories that want repeatable, logged handling. It is a research format only; no administration guidance of any kind is given.

Is there a batch report for the GLOW pen?

Not yet. No batch-specific report for the pen is posted in the COA library. The page will state the report when one exists.

Is the GLOW pen for human use?

No. The pen is supplied for laboratory research only and is not for human or animal use. No dosing, administration or protocol information is provided.

Cited

1. Maquart et al. (1988), FEBS letters — PMID 3169264
2. Maquart et al. (1993), The Journal of clinical investigation — PMID 8227353
3. Fu et al. (2015), Journal of orthopaedic research : official publication of the Orthopaedic Research Society — PMID 25731775
4. Staresinic et al. (2003), Journal of orthopaedic research : official publication of the Orthopaedic Research Society — PMID 14554208
5. Malinda et al. (1999), The Journal of investigative dermatology — PMID 10469335
6. Biçer et al. (2026), Joint diseases and related surgery — PMID 42542926
7. Vasireddi et al. (2025), HSS journal : the musculoskeletal journal of Hospital for Special Surgery — PMID 40756949

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.